On 23 March 2017, the European Medicines Agency (EMA) together with the heads of national competent authorities in the European Economic Area (EEA), has established a new task force to explore how medicines regulators in the EEA can use big data to support research, innovation and robust medicines development to benefit human health.
The main goal of the task force will be to establish roadmap and recommendations for use of big data in assessment of medicines. The task force is chaired by the EMA and the Danish Medicines Agency, their efforts will be complemented on an ad hoc basis by external experts in big data collection analysis.
For the next 18 months, the task force agreed on the following actions:
More information can be found here